Prescribing information

Extavia is indicated for the treatment of1:

  • Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.
  • Patients with relapsing remitting multiple sclerosis and two or more relapses within the last two years.
  • Patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.

 

Extavia auto-injector training video

To help patients administer Extavia using the auto-injector, you can share the training video below by directing your patients here.

This video shows patients how to prepare and deliver Extavia injections and answers many common questions about administration.

It also advises patients to read the patient information leaflet (PIL) for Extavia, which is available here.

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

 

Reference

  1. Extavia (interferon beta-1b) Summary of Product Characteristics.
EXT20-C004 September 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]